Quentis Therapeutics
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
430 E 29th St Ste 1005, New York, New Yo...Phone Number
(646) 440-9249Website
www.quentistx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Quentis Therapeutics
Quentis Therapeutics is a biotechnology company focused on the development of next-generation immuno-oncology drugs aimed at benefiting all cancer patients through immunotherapy. The company specializes in targeting endoplasmic reticulum (ER) stress pathways to create innovative therapeutic approaches, starting with their first-in-class IRE1a inhibitor designed to enhance the immune system's ability to combat cancer. Quentis brings together a team of esteemed scientific researchers and leaders from top biopharmaceutical organizations, leveraging their expertise in immunology, cellular biology, and drug development. Their mission is to translate pioneering scientific research into meaningful medicines for patients suffering from various diseases, including cancer.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Quentis Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Quentis Therapeutics
Product Launch: Get notified when Quentis Therapeutics launches new products
Earning: See what the market has to say on Quentis Therapeutics recently announced quarterly report
Check if Quentis Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Quentis Therapeutics had a recent Job posting/layoffs
Quentis Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Quentis Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Quentis Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined Quentis Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Quentis Therapeutics
Compare insights from companies similar to Quentis Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Quentis Therapeutics
<$5M
11-50
Private
-
2016
N/A
Company Profile Activity
Activity Insights
Quentis Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Quentis Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Quentis Therapeutics.
Quentis Therapeutics Tech Stack
A closer look at the technologies used by Quentis Therapeutics
Quentis Therapeutics News & Media
Quentis Therapeutics Announces the Appointment of Jeanne Magram, Ph.D. as Chief Scientific Officer
NEW YORK--(BUSINESS WIRE)--Quentis Therapeutics, a NYC-based biotech focused on advancing ER stress response-targeted therapies, appoints Jeanne Magram, Ph.D., as CSO.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Quentis Therapeutics
Sign Up For FreeTo access detailed company insights
Quentis Therapeutics is a biotechnology company focused on the development of next-generation immuno-oncology drugs aimed at benefiting all cancer patients through immunotherapy. The company specializes in targeting endoplasmic reticulum (ER) stress pathways to create innovative therapeutic approaches, starting with their first-in-class IRE1a inhib... Read More
